BioinvestGPT ApS · Research use only

Calls ahead of readouts · BioPharma Dive’s 2H 2026 watch list · 28 Jul 2026

All Ten Most-Anticipated Readouts of 2H 2026. Called Before the Data.

On 28 Jul 2026, BVCT shared fourteen sealed calls on the ten entries BioPharma Dive listed for 2H 2026: seven GO, seven NO-GO. CARDIO-TTRansform (No. 1863, sealed 12 Dec 2024) read out 9 Jul 2026, classified True Negative (TN). INTerpath-001 (No. 2161) and HARBOR (No. 2157) have since been classified True Positive (TP) and True Negative (TN); eleven await scoring.

Fourteen sealed, timestamped, patient-data-independent predictions against BioPharma Dive’s “10 clinical trials to watch in the second half of 2026”

On 29 Jun 2026, BioPharma Dive published the ten clinical readouts the industry is watching most closely in the second half of this year. Between them, these programmes represent, in our estimate, tens of billions of dollars in committed clinical capital and expected peak sales — across adjuvant melanoma, Alzheimer’s psychosis, ATTR cardiomyopathy, chronic urticaria, IBD, lupus, myotonic dystrophy, NSCLC, pneumococcal vaccination and stroke prevention.

BVCT has now issued a sealed, timestamped ex-ante clinical benefit prediction on every one of them — fourteen predictions in total, covering all ten entries (all fourteen are listed below; the ones scored so far link to their dashboard records). Each prediction was generated with no patient data ingested and no machine-learning training on past trial outcomes: each simulation of the drug-body causal interaction within BVCT virtual human patients identifies the underlying mechanisms of the human body that determine the clinical benefits of a novel medicine.

Every prediction below is timestamped with a PandaDoc certificate carrying an immutable signature timestamp. They were shared on 28 Jul 2026, before their readouts, except No. 1863, which had read out on 9 Jul 2026. Each call will be checked against its readout; those scored so far link to their dashboard records below.

One entry on the list — AstraZeneca and Ionis’ CARDIO-TTRansform — announced its topline readout on 9 Jul 2026, which has been perfectly aligned with BVCT’s prediction sealed 574 days earlier (see below).

Six NO-GO calls. Seven GO calls. One already confirmed. Timestamped in advance. Delivered before readouts.

The GO Calls.

Seven programmes where BVCT projects sufficient clinical benefit — quantified against the named comparator standard of care, not against placebo alone.

The NO-GO Calls.

Seven programmes on the watch list where BVCT’s virtual patients project insufficient clinical benefit to clear the registrational or the commercial bar — one already confirmed by readout, six still pending (when these calls were shared).

Why This Matters to Your Portfolio Committee.

Each BVCT prospective clinical benefit prediction corresponds to a head-to-head phase-3-scale quantification of the clinical effect size of a novel therapy against a named comparator standard of care, backed by a mechanistic causal rationale, sealed and timestamped before the readout.

That distinction is what makes the BVCT prediction actionable before every pipeline decision. A GO call you can defend to a board is one where the root cause is identified, the competitive advantage is quantified, and the timestamp proves it was made before the answer was known. A NO-GO call has the same property — which is why BVCT can save nine-figure sunk cost in R&D and BD&L before it is committed.

BVCT’s prospective record now stands at 674 of 705 ex-ante clinical predictions correct in the cohort frozen on 24 Sep 2026 — 95.6% accuracy, 89.7% PPV (GO calls), 99.1% NPV (NO-GO calls), F1 of 93.8% — against a 28.9% industry baseline (BIO / QLS / Informa 2011–2020, Phase II transition success rate). When these calls were shared, No. 1863 was the most recent confirmation and the thirteen pending calls above were the next test, on the record in advance; No. 2161 and No. 2157 have been scored since (see above).

Every one of these programmes could have carried a per-asset Phase-III effect size call before the clinical capital was committed. So can yours — in seven days, at under 0.1% of the cost of the trial that would answer the question.

Seven days per asset. Before the commit.

Name any asset in your portfolio, the indication, the patient stratum, and the comparator standard of care. Receive a simulated Phase-III effect size, a GO / NO-GO call against your own blockbuster threshold, and a mechanistic causal rationale — within one week. No patient data required. No model training. Sealed and timestamped, so the call can be verified against the readout.

Clinical Foresight Before Decisions. Earlier is Kinder for Patients.

Start at bvct.bioinvestgpt.com →